We suggest that in the context of a functioning CDKN2A gene, aberrant tumor cell proliferation may result in incrementally increasing, compensatory expression of CDKN2A/p16 in a futile effort to halt cell cycle progression [6, 49]. The gene discussed is CDKN2A; the disease is neoplasm.